❌

Reading view

DeKeyNLU: Enhancing Natural Language to SQL Generation through Task Decomposition and Keyword Extraction

arXiv:2509.14507v2 Announce Type: replace Abstract: Natural Language to SQL (NL2SQL) provides a new model-centric paradigm that simplifies database access for non-technical users by converting natural language queries into SQL commands. Recent advancements, particularly those integrating Retrieval-Augmented Generation (RAG) and Chain-of-Thought (CoT) reasoning, have made significant strides in enhancing NL2SQL performance. However, challenges such as inaccurate task decomposition and keyword extraction by LLMs remain major bottlenecks, often leading to errors in SQL generation. While existing datasets aim to mitigate these issues by fine-tuning models, they struggle with over-fragmentation of tasks and lack of domain-specific keyword annotations, limiting their effectiveness. To address these limitations, we present DeKeyNLU, a novel dataset which contains 1,500 meticulously annotated QA pairs aimed at refining task decomposition and enhancing keyword extraction precision for the RAG pipeline. Fine-tuned with DeKeyNLU, we propose DeKeySQL, a RAG-based NL2SQL pipeline that employs three distinct modules for user question understanding, entity retrieval, and generation to improve SQL generation accuracy. We benchmarked multiple model configurations within DeKeySQL RAG pipeline. Experimental results demonstrate that fine-tuning with DeKeyNLU significantly improves SQL generation accuracy on both BIRD (62.31% to 69.10%) and Spider (84.2% to 88.7%) dev datasets.
  •  

Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer

Nat Commun. 2025 Aug 22;16(1):7827. doi: 10.1038/s41467-025-63146-2.

ABSTRACT

While dysregulation of polyamine metabolism is frequently observed in cancer, it is unknown how polyamines alter the tumor microenvironment (TME) and contribute to therapeutic resistance. Analysis of polyamines in the plasma of pancreatic cancer patients reveals that spermine levels are significantly elevated and correlate with poor prognosis. Using a multi-omics approach, we identify Serpinb9 as a vulnerability in spermine metabolism in pancreatic cancer. Serpinb9, a serine protease inhibitor, directly interacts with spermine synthase (SMS), impeding its lysosome-mediated degradation and thereby augmenting spermine production and secretion. Mechanistically, the accumulation of spermine in the TME alters the metabolic landscape of immune cells, promoting CD8+ T cell dysfunction and pro-tumor polarization of macrophages, thus creating an immunosuppressive microenvironment. Small peptides that disrupt the Serpinb9-SMS interaction significantly enhance the efficacy of immune checkpoint blockade therapy. Together, our findings suggest that targeting spermine metabolism is a promising strategy to improve pancreatic cancer immunotherapy.

PMID:40846845 | PMC:PMC12373741 | DOI:10.1038/s41467-025-63146-2

  •  

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping: Chemotherapy, Immunotherapy, or Targeted Therapy?-A Retrospective Analysis

Ann Surg Oncol. 2025 Jul 3. doi: 10.1245/s10434-025-17738-3. Online ahead of print.

ABSTRACT

BACKGROUND: This study aimed to identify the most effective drug therapeutics for patients with the mesenchymal subtype of advanced gastric cancer (AGC). Extensive research employing diverse omics methodologies has unveiled a varied landscape of AGC. Recent progress in next-generation sequencing and other genomic technologies has facilitated a more intricate exploration of AGC at the molecular level. Nonetheless, the optimal treatment for patients with the mesenchymal subtype of gastric cancer remains elusive. Lei's molecular classification of AGC is based on gene expression profiles named "mesenchymal," "immunogenic," "classical," and "metabolic."

PATIENTS AND METHODS: Based on RNA-seq transcriptome, 234 patients were divided into four molecular subtypes: mesenchymal (n = 96), immunogenic (n = 37), metabolic (n = 61), and classic (n = 40).

RESULTS: Among those with mesenchymal-subtype AGC, compared with non-Apatinib group, the Apatinib treatment group demonstrated a significant increase in objective response rate (ORR 89.3% versus 69.3%, p = 0.038; odds ratio (OR) 0.269, 95% confidence interval (CI) (0.073-0.989)); overall survival (OS) 89.3% versus 60.2%, p = 0.010; hazard ratio (HR) 0.241, 95% CI (0.073-0.796)) and disease-free survival (DFS 78.6% versus 52.9%, p = 0.031; HR 0.400, 95% CI (0.167-0.956)). Furthermore, Apatinib significantly reduced the risk of death and recurrence in patients with mesenchymal subtype (OS: HR 0.129, 95% CI (0.030-0.563), p = 0.006; DFS: HR 0.340, 95% CI (0.138-0.833), p = 0.018). However, no significant differences were observed in the ORR, OS, or DFS between patients with metabolic and classical subtypes who underwent combination chemotherapy with additional Apatinib or camrelizumab.

CONCLUSIONS: Our analysis has revealed that, for neoadjuvant therapy in AGC, the mesenchymal subtype stands out as the ideal patient population benefiting from Apatinib.

PMID:40608168 | DOI:10.1245/s10434-025-17738-3

  •  
❌